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Introduction
Conventional brain magnetic resonance imaging 
(MRI) provides reliable markers of acute inflamma-
tory activity but has a low sensitivity and specificity 
for those tissue changes that characterize the (chronic) 
progressive phase of multiple sclerosis (MS). 
Identifying new or substantially enlarging T2 lesions, 
as done in clinical trials, is a marker for acute focal 
inflammation in MS, but does not capture the subtler 
chronic evolution of persistent T2 lesions. One of the 
neuropathological hallmarks of chronic inflamma-
tion in MS has been described as chronic active 
lesions or smoldering plaques. While acute MS 
plaques predominate in early relapsing MS (RMS) 
patients and are the likely substrate of clinical attacks, 
pathologically defined smoldering plaques are more 
prominent in progressive MS patients (12%–28% of 
plaques)1,2 and may expand as a result of sustained 
inflammatory processes driven by a rim of iron-laden 
microglia/macrophages.1–5 Chronic inflammation 
sheltered behind a partially or non-disrupted blood–
brain barrier (BBB) is increasingly considered a sig-
nature of progressive MS.5
Histopathologically, smoldering lesions are charac-
terized by an inactive center with no or few mac-
rophages, surrounded by a rim of activated microglia/
macrophages which contribute to chronic axonal 
damage and demyelination, and are thought to slowly 
evolve over the long term.2,6
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Abstract
Background: Chronic lesion activity driven by smoldering inflammation is a pathological hallmark of 
progressive forms of multiple sclerosis (MS).
Objective: To develop a method for automatic detection of slowly expanding/evolving lesions (SELs) on 
conventional brain magnetic resonance imaging (MRI) and characterize such SELs in primary progres-
sive MS (PPMS) and relapsing MS (RMS) populations.
Methods: We defined SELs as contiguous regions of existing T2 lesions showing local expansion assessed 
by the Jacobian determinant of the deformation between reference and follow-up scans. SEL candidates 
were assigned a heuristic score based on concentricity and constancy of change in T2- and T1-weighted 
MRIs. SELs were examined in 1334 RMS patients and 555 PPMS patients.
Results: Compared with RMS patients, PPMS patients had higher numbers of SELs (p = 0.002) and 
higher T2 volumes of SELs (p < 0.001). SELs were devoid of gadolinium enhancement. Compared with 
areas of T2 lesions not classified as SEL, SELs had significantly lower T1 intensity at baseline and larger 
decrease in T1 intensity over time.
Conclusion: We suggest that SELs reflect chronic tissue loss in the absence of ongoing acute inflamma-
tion. SELs may represent a conventional brain MRI correlate of chronic active MS lesions and a candidate 
biomarker for smoldering inflammation in MS.
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The largest analysis of histopathological lesion phe-
notypes in MS (2476 white matter plaques from 
120 patients) showed that smoldering plaques were 
mainly seen in patients with disease duration beyond 
10 years, and peaked at approximately 20 years of 
disease duration and in patients of 50 years of age.2,7
There is no consensus about the reliable in vivo 
detection of chronic active or smoldering lesions. 
The identification of paramagnetic rims on high-res-
olution T2* and phase MRI using 7T or even 3T 
appears to be a promising avenue.8 We developed a 
method to identify and quantify change over time in 
chronic active lesions characterized by constant 
enlargement using only conventional T1-weighted 
and T2-weighted MRI data. The OPERA I, OPERA 
II, and ORATORIO phase III clinical trial data sets of 
patients with relapsing and primary progressive 
forms of MS were used to develop an algorithm 
based on longitudinal changes in conventional MRIs 
for detection of areas of chronic evolution in existing 
T2 lesions. Within these slowly expanding/evolving 
lesions (SELs), we investigated T1 gadolinium (Gd) 
enhancement and temporal evolution of T1-weighted 
signals. Throughout this manuscript, the use of the 
term “chronic active” lesions is to be considered 
independent of the underlying pathological lesion 
classification as defined by Kuhlmann et al.9 and is 
solely based on MRI properties of SELs.
Materials and methods
Trial design and patients
SELs were determined in the pooled population of the 
two identical phase III, multicenter, randomized, dou-
ble-blind, double-dummy, parallel-group OPERA I and 
OPERA II trials (OPERA I/NCT01247324 and 
OPERA II/NCT01412333), and in the phase III, rand-
omized, placebo-controlled, double-blind, multicenter 
ORATORIO trial (NCT01194570). Study details have 
been reported previously.10,11 Methods for brain MRI 
acquisition are described in Supplementary Material.
The OPERA I, OPERA II, and ORATORIO trial pop-
ulations were pooled (N = 2388) to assess T1-weighted 
Gd enhancement in SELs, non-SELs, and new focal 
T2 lesions. T1-weighted signal intensity in SELs and 
the prevalence of SELs were assessed in the pooled 
population of OPERA I and OPERA II (RMS popula-
tion) and in ORATORIO (primary progressive MS 
(PPMS) population). Algorithm development and 
SEL identification were performed blinded to treat-
ment and clinical outcome, but not to study member-
ship. The T1-weighted signal was normalized using 
least-trimmed squares over time for a given patient, 
followed by tissue-based normalization, where 0 and 
1 values represent median T1 signal intensities of 
normal-appearing gray matter and normal-appearing 
white matter, respectively.
Identification of SELs
Prior to identification of SELs, T2 lesions were iden-
tified in baseline scans using a semi-automated 
method, where a fully automated segmentation12 
was subsequently manually reviewed and corrected 
by trained MRI readers. SELs were then identified 
as a fraction of pre-existing T2 lesions undergoing 
positive local volume change consistent with grad-
ual and constant radial expansion. These regions 
could correspond to discrete T2 lesions or to regions 
within a confluent lesion mass. SELs were detected 
at a follow-up timepoint with respect to a reference 
timepoint; any intermediate scans between reference 
and follow-up were also considered. Identification 
of SELs was done as a two-stage process. First, 
Jacobian analysis was used to identify SEL candi-
dates, corresponding to contiguous regions of a T2 
lesion undergoing local expansion, and second, indi-
vidual SEL candidates were heuristically scored, to 
favor those undergoing concentric and constant 
change, consistent with gradual inside-out radial 
expansion.
Jacobian analysis
Jacobian analysis is based on computing the Jacobian 
determinant of the non-linear deformation field 
between a reference and follow-up scan and can be 
used to detect and quantify subtle change on a per-
voxel basis. It has been used previously in applica-
tions such as measuring growth or shrinkage of brain 
structures, or regions of interest (ROIs).13–15 Here, it is 
applied to quantifying subtle and gradual change in 
pre-existing T2 lesions. The Jacobian analysis pipe-
line used is based on that of Nakamura et al.14 and is 
summarized as follows (Figure 1(a)–(e)):
1. Resampling of images to 1-mm isotropic space.
2. Linear (affine) registration between a reference 
and follow-up timepoint for global alignment 
of a scan in a halfway (unbiased) space.
3. Non-linear registration (step size = 0.7; Gaussian 
sigma = 2) between linearly aligned timepoints 
to generate a deformation field which describes 
the local displacement at each voxel that best 
aligns the two images,16 where the registration 
is performed using the T1-weighted and 
T2-weighted images simultaneously.
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4. Computation of the Jacobian of the deforma-
tion field, corresponding to the three-dimen-
sional (3D) spatial derivative of the deformation 
field at each voxel.
5. Computation of the determinant of the 
Jacobian, providing a single scalar value 
describing the magnitude of local volume 
change at each voxel as a percent.
6. Resampling of Jacobian determinant maps 
to original image resolution of 
1 mm × 1 mm × 3 mm.
SEL candidates
SEL candidates were identified as contiguous regions 
within pre-existing T2 lesions that showed minimum 
positive local volume change, as determined by the 
Jacobian determinant (Supplementary Figure 1). 
Boundaries of individual SEL candidates were deter-
mined as follows:
1. Identify voxels within pre-existing T2 lesions 
that have minimum rate of expansion greater or 
equal to Jacobian Expansion (JE1).
2. Group voxels identified in (1), based on 
3D-connected component analysis using 
18 connectedness, to form initial boundaries 
of SEL candidates.
3. Dilate SEL candidates as determined in (2) by 
iteratively considering neighboring voxels that 
have minimum rate of local expansion, JE2, 
where JE2 < JE1, to generate final boundaries 
of SEL candidates.
4. Discard any SEL candidates that are less than 
10 voxels in size (reliability criterion).
The identification of SEL candidates is done as a two-
stage process to ensure that distinct expansions are 
considered as separate discrete entities, even if they 
happen to be spatially connected. A minimum SEL size 
of 10 voxels is considered because of the inherent 
smoothing in the computation of the non-linear defor-
mation and resultant Jacobian, and because the concen-
tricity feature computed for classification of individual 
SEL candidates cannot be reliably computed for ROIs 
less than 10 voxels. The process for identification of 
SEL candidates is shown graphically in Figure 1(f)–(i). 
For the experiments performed in this paper, JE1 was 
heuristically set to 12.5%/year and JE2 to 4%/year, 
Figure 1. Jacobian analysis and SEL candidates: (a), (b) An axial slice of linearly co-registered reference and follow-up  
T1-weighted scans. (c) The reference scan with a regular grid overlaid. (di) The non-linearly deformed image in (c) 
is shown to match the follow-up scan, and (dii) an enlarged lesion area of the deformation field. (e) The Jacobian 
determinant is shown as a heat map, where blue represents local contraction and red local expansion. The Jacobian 
determinant represents the local percent volume change at each voxel, after application of the non-linear deformation that 
warps (a) to match (b). (f) An axial slice of a reference T2-weighted scan with overlaid T2 lesion segmentation. (g) The 
Jacobian determinant within reference T2 lesions. (h) Initial SEL candidate boundaries based on JE1. (i) Refined SEL 
candidate boundaries based on JE2.
JE: Jacobian Expansion; SEL: slowly expanding/evolving lesion.
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based on visual assessment of lesion expansion on lon-
gitudinal MRI sequences and their corresponding 
Jacobian determinant maps. Percentage local volume 
increase as measured by the Jacobian is normalized to 
a rate per year, so the algorithm is more independent of 
the actual time between scans. Methods for SEL selec-
tion from a set of SEL candidates are described in 
Supplementary Material.
Lesion and SEL atlases
Atlases representing relative probabilities of anatomical 
location of various lesion subtypes were computed over 
all OPERA I, OPERA II, and ORATORIO study par-
ticipants, for the following lesion subtypes: T2 hyperin-
tense lesions (baseline only), T1 hypointense lesions 
(baseline only), and SELs (with a heuristic score ⩾ 0) 
detected from baseline to Week 96/120. Atlases were 
constructed by performing non-linear registration of 
each patient to ICBM (International Consortium for 
Brain Mapping) space and resampling the correspond-
ing lesion/SEL masks into the common ICBM space. 
By combining the corresponding masks over all 
patients, the relative probability of each lesion subtype 
occurring at a given voxel location can be determined.
Statistical analysis
The statistical analysis of SEL data was exploratory 
and included all patients from OPERA I, OPERA II, 
and ORATORIO with no missing or non-evaluable 
scans (SEL analysis population). No imputation of 
missing data was performed, except for an analysis of 
the number of SELs, where for patients who were in 
the intent-to-treat population of the studies but not 
part of the SEL analysis population, the number of 
SELs was imputed as zero.
Statistical comparisons of continuous variables 
between RMS and PPMS patients were performed 
using the Van Elteren test,17 stratified for treatment 
group (ocrelizumab, comparator) and baseline T2 
lesion volume category based on tertiles (⩽3.013 cm3, 
<3.013 to ⩽11.122 cm3, and >11.122 cm3).
Results
Baseline demographics and characteristics
The baseline disease and MRI characteristics for the 
SEL analysis populations from OPERA I, OPERA II, 
and ORATORIO phase III clinical trial data sets of 
patients with RMS and PPMS used for this study are 
presented in Table 1. Algorithm development was 
performed blinded to the treatment group assignment 
information. Results are presented for all SEL candi-
dates and high-probability SELs (with a heuristic 
score ⩾ 0). Throughout this manuscript, we will con-
sistently use as a semantic convention the term “all 
SEL candidates” for all detected SELs, irrespective of 
Figure 2. Constancy and concentricity of expansion: (a), (b) Plots of amount of expansion as a function of time, where 
the dotted line represents the linear best fit of expansion as a function of time and markers (X) represent the actual 
expansion as measured by the Jacobian determinant at each intermediate timepoint. The plots represent examples of 
lesions with a fairly constant expansion ((a), Z-score for constancy = 1.02) and a poorly constant expansion ((b), Z-score  
for constancy = −1.56). Other examples are shown with a fairly concentric pattern of expansion ((c), Z-score for 
concentricity = 5.33) and a poorly concentric pattern of expansion ((d), Z-score for concentricity = −0.812). Note that 
colors in (c) and (d) represent percent local expansion.
C Elliott, JS Wolinsky et al.
journals.sagepub.com/home/msj 1919
their heuristic SEL score value, and only refer to 
“SELs” for those high-probability SELs with a heu-
ristic score ⩾ 0. In addition, SEL detection was 
restricted to patients with all four MRI assessments 
available: baseline, Week 24, Week 48, and Week 96 
for OPERA I and OPERA II; and baseline, Week 24, 
Week 48, and Week 120 for ORATORIO.
SEL prevalence in RMS versus PPMS
The proportion of patients with ⩾1 SEL was similar in 
PPMS (71.9%, ORATORIO, baseline to Week 120) 
and RMS patients (68.2%, pooled OPERA I and 
OPERA II, baseline to Week 96, respectively). 
Compared with RMS patients (pooled OPERA I and 
OPERA II), PPMS patients (ORATORIO) had a higher 
mean number of SELs (6.3 vs 4.6, p = 0.002) (Figure 3(a)), 
a higher mean T2 volume of SELs (baseline: 1838 
vs 1223 mm3, p < 0.001) (Figure 3(b)), and a higher 
mean proportion of baseline total T2 lesion burden 
identified as SELs (11.3% vs 8.6%, p < 0.001) (Figure 
3(c)). The frequency distribution of RMS versus PPMS 
patients with respect to SEL detection prevalence is 
detailed in Supplementary Figure 2. The latter analyses 
(Figure 3 and Supplementary Figure 2) were based 
on three timepoints (baseline, Week 24, and Week 48) 
to ensure consistent timepoints across all patients in 
both study populations. Similar differences in num-
ber of SELs, T2 volume of SELs, and proportion of 
baseline total T2 lesion burden identified as SELs 
were observed for all SEL candidates (Supplementary 
Figure 3).
Gd enhancement in SELs
The proportion of voxels within the baseline T2 limits 
of the ROIs that displayed Gd enhancement at any 
scheduled MRI visit (baseline to Week 96 for OPERA I 
and OPERA II, and baseline to Week 120 for 
ORATORIO) are presented for the pooled OPERA I, 
OPERA II, and ORATORIO study populations 
(N = 2388). The percentage of voxels showing Gd 
enhancement was higher in areas of pre-existing T2 
lesion at baseline not classified as SEL (non-SEL) 
(1.5%, p < 0.001) and in new focal T2 lesions (8.9%, 
p < 0.001), compared with regions identified as SELs 
(0.3%) (Figure 4). Similar differences were observed 
for all SEL candidates (Supplementary Figure 4). 
These results were consistent in both the individual 
RMS and PPMS populations (data not shown).
Table 1. Baseline demographics and characteristics for the OPERA I, OPERA II, and ORATORIO SEL analysis 
population.
Baseline demographics and disease characteristics OPERA I and OPERA II 
(pooled) (N = 1334)a
ORATORIO (N = 555)b
Age, mean (SD), years 37.3 (9.2) 44.9 (7.9)
Female, n (%) 873 (65.4) 276 (49.7)
Time since multiple sclerosis symptom onset, mean (SD), years 6.5 (6.1) 6.4 (3.7)c
Number of relapses in previous 12 months, mean (SD) 1.3 (0.7)d N/A
EDSS, mean (SD) 2.7 (1.3) 4.6 (1.2)e
MRI
  Number of T1 Gd-enhancing lesions, mean (SD) 1.7 (4.6)f 1.0 (4.6)e
  Proportion of patients with ⩾1 T1 Gd-enhancing lesion (%) 39.6f 25.3e
  Brain T2 hyperintense lesion volume, median (range), cm3 5.4 (0–96.0)f 6.9 (0–82.4)e
  Normalized brain volume, mean (SD), cm3 1500.4 (87.9)g 1462.4 (85.1)h
SEL: slowly expanding/evolving lesion; SD: standard deviation; N/A: not applicable; EDSS: Expanded Disability Status Scale;  
MRI: magnetic resonance imaging; Gd: gadolinium; IFN: interferon; RMS: relapsing multiple sclerosis;  
PPMS: primary progressive multiple sclerosis.
Non-evaluable patients based on missing scan information for the analysis up to Week 48 (Week 96/120): OPERA ocrelizumab 125 
(128); OPERA IFN β-1a 197 (199); ORATORIO ocrelizumab 104 (104); and ORATORIO placebo 73 (73). Patients with incomplete 
scan data were considered to have no SELs; results were similar when those patients were excluded from the analysis.
aData are presented for patients evaluable for SEL detection. Total RMS population N = 1656 (ocrelizumab N = 827, IFN β-1a N = 829).
bData are presented for patients evaluable for SEL detection. Total PPMS population (ocrelizumab N = 488, placebo N = 244).
cn = 538.
dn = 1333.
en = 554.
fn = 1330.
gn = 1324.
hn = 550.
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T1-weighted signal intensity in SELs
In the pooled OPERA trial population, compared with 
non-SEL, SELs had a lower normalized T1 intensity at 
baseline (0.282 vs 0.100, p < 0.001) (Figure 5). 
Similarly, in the ORATORIO trial population, SELs had 
a lower normalized T1 intensity at baseline compared 
with non-SEL (0.225 vs −0.002, p < 0.001) (Figure 5). 
Comparisons of absolute T1 intensity of SELs (from 
by-patient means) and non-SELs at each timepoint in 
RMS and PPMS populations were significant 
(p < 0.001; Figure 5). Comparison of the change from 
baseline to Week 96/120 showed a significantly larger 
decrease in normalized T1 intensity in SELs compared 
with non-SELs in both RMS and PPMS populations 
(p < 0.001 at all longitudinal timepoints; Figure 5). 
Similar results were observed using a T1-agnostic ver-
sion of the algorithm, which was based on T2-weighted 
imaging information only (data not shown). It should be 
noted that there were differences between RMS and 
PPMS SELs and non-SELs with respect to absolute T1 
intensity levels. A similar pattern of decrease over time 
in normalized T1 intensity from baseline to Week 
Figure 3. SEL prevalence in RMS and PPMS populations: (a) Total number of SELs per patient detected from baseline 
to Week 48. (b) Total baseline T2 volume detected as SELs from baseline to Week 48. (c) Proportion of T2 volume 
associated to SELs within T2 mask at baseline.
PPMS: primary progressive multiple sclerosis; RMS: relapsing multiple sclerosis; SEL: slowly expanding/evolving lesion.
For patients without any SELs or without any SEL candidates, the number of SELs is set to 0. Baseline T2 volume associated with SELs 
is defined as the sum of baseline T2 volume associated with each SEL. Red asterisks represent the mean values.
aVan Elteren test; stratified by treatment group (ocrelizumab, control), baseline T2 lesion volume category based on tertiles (⩽3.013 cm3, 
<3.013 to ⩽11.122 cm3, >11.122 cm3).
bLog-transformed.
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96/120 was observed for all SEL candidates 
(Supplementary Figure 5). At the lesion level, we also 
observed that T1 intensity change at the edge of a SEL 
area results in a concentric inside-out pattern of the 
Jacobian expansion (Figure 6).
Anatomical distribution of SELs
We performed a voxel-wise probabilistic analysis of 
SEL location versus overall T2 lesions and T1 
hypointense lesions across the totality of OPERA I, 
OPERA II, and ORATORIO trial populations (Figure 
7). These data demonstrated that the anatomical dis-
tribution of SELs is respecting the preferentially 
periventricular maximal probability of T1/T2 lesion 
occurrence across RMS and PPMS disease pheno-
types, with a higher heat map density in patients with 
PPMS. It should be acknowledged that this is to be 
seen with the limitations of a qualitative descriptive 
analysis. We also observed a more posterior distribu-
tion pattern of SELs along the periventricular region.
Discussion
This study presents a novel technique to reliably detect 
and quantify chronically evolving MS lesions using 
serial conventional T1- and T2-weighted MRI. 
Compared with non-SELs, SELs were shown to evolve 
independently of T1 Gd enhancement, demonstrated a 
lower T1 intensity at baseline, and demonstrated a pro-
gressive decrease in T1 intensity over time, as a poten-
tial read-out for progressive accumulation of neural 
tissue damage, and especially axonal loss.18 The latter 
pattern was seen in the context of PPMS and RMS trial 
populations, but was nominally and statistically more 
pronounced in PPMS. The accumulation of T1 hypo-
intensity or more profound “black hole” formation in 
SELs occurred independently of acute inflammation as 
usually defined based on contrast enhancement. 
Dynamic gadolinium contrast enhancement experi-
ments would be needed to determine whether SELs 
might be associated with increased BBB permeability 
insufficient to produce T1 gadolinium-enhancing 
lesions as typically defined. Whether central nervous 
system tissue loss in SELs is related to chronic 
microglia/macrophage-mediated inflammatory pro-
cesses and/or Wallerian neurodegeneration is to be 
Figure 4. T1-weighted Gd enhancement in SELs.
Gd: gadolinium; PPMS: primary progressive multiple sclerosis; 
RMS: relapsing multiple sclerosis; SEL: slowly expanding/
evolving lesion.
Box plot representation, where y-axis scale is based on arcsine 
transformation. Red asterisks represent the mean values. 
Consistent results were observed in both RMS and PPMS study 
populations, separately.
aVolume normalized average: sum (proportion of baseline T2 
lesion voxels that is Gd-enhancing for each lesion*T2 volume)/
sum of T2 volume. T2 volume for SEL, new T2 lesion at Week 24, 
and new T2 lesion at Week 48 are T2 volume at baseline,  
Week 24, and Week 48, respectively. SELs identified using  
scans from all scheduled visits.
bVan Elteren test; stratified by treatment group (ocrelizumab, 
control), baseline T2 lesion volume category based on tertiles 
(⩽3.013 cm3, <3.013 to ⩽11.122 cm3, >11.122 cm3).
Figure 5. T1-weighted signal intensity in SELs.
CI: confidence interval; PPMS: primary progressive multiple 
sclerosis; RMS: relapsing multiple sclerosis; SEL: slowly 
expanding/evolving lesion.
Last visit is Week 96 for OPERA I and OPERA II, and Week 120 
for ORATORIO.
aVan Elteren test; stratified by treatment group (ocrelizumab, 
control), baseline T2 lesion volume category based on tertiles 
(⩽3.013 cm3, <3.013 to ⩽11.122 cm3, >11.122 cm3).
*p < 0.001a for the comparison of absolute T1 intensity of SELs 
versus non-SELs at each timepoint in RMS and PPMS.
†p < 0.001a for the change in normalized T1 intensity from 
baseline to Week 24, Week 48, and Week 96/120 for SELs versus 
non-SELs in RMS and PPMS, respectively.
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determined, but the observed ubiquitous character of 
SELs may represent an argument for progressive brain 
tissue damage occurring in both RMS and PPMS along 
a phenotypic continuum of MS disease.
The constant decrease in T1 signal intensity of SELs 
is consistent with the expected T1-weighted MRI 
behavior of smoldering plaques, since the core of 
such lesions is typically characterized by severe accu-
mulation of axonal damage3,19 and pathological and 
proton magnetic resonance spectroscopy studies dem-
onstrate that the decrease in T1-weighted signal inten-
sity within MS lesions reflects the magnitude of tissue 
destruction and axonal loss.20,21 The potential neuro-
pathological correlates of SELs need to be further 
characterized. Quantitative susceptibility mapping 
Figure 6. Heat map representation of a specific example of the lesion-level spatial distribution of T1 intensity change 
over time and corresponding Jacobian Expansion in SELs.
MRI: magnetic resonance imaging; SEL: slowly expanding/evolving lesion.
The edge of SELs (with heuristic score ⩾ 0) are represented by white arrows. T1 intensity change at the lesion edge results in a 
concentric inside-out pattern in the Jacobian. Red font “x” labels represent the time of brain MRI scanning acquisitions. An animated 
version of Figure 6 will also be available in Supplementary Material.
Figure 7. Probabilistic atlas of T2 hyperintense lesion, T1 hypointense lesion, and SEL spatial distributions.
PPMS: primary progressive multiple sclerosis; RMS: relapsing multiple sclerosis; SEL: slowly expanding/evolving lesion.
Each atlas represents the proportion of the lesion subtype occurring at a given anatomical location. Scales are consistent across all 
atlases.
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(QSM) imaging22–25 could be used to assess the rela-
tion of SELs detected on MRI to the iron rim at the 
edge of chronic active lesions, as reported in patho-
logical studies.26 However, only a fraction of smold-
ering lesions appear to have iron/zinc rims.27 Further 
elucidation of SEL characteristics might be derived 
from positron emission tomography studies using 
[11C]PK11195 or translocator protein radioligands, 
such as 11C-PBR28 or 18F-PBR111, for the detection 
of activated macrophages/microglia and astro-
cytes.28–30 To what extent neurotoxic reactive astro-
cytes of the A1-type induced by activated microglia31 
may also be part of the underlying pathology within 
SELs remains to be elucidated.
Whether SELs may have potential as an MRI marker 
of chronic disease activity that could inform clinical 
prognosis in patients with MS also needs to be 
explored. Pathological studies have shown that slowly 
expanding demyelination, in amounts that appear to 
be comparable in PPMS and secondary progressive 
MS, is correlated with incomplete remyelination and 
may thus irreparably destroy normal and repaired 
myelin.4 Similarly, it was shown that the persistent 7T 
phase rim, which may reflect both smoldering inflam-
mation and the presence of iron-laden microglia/mac-
rophages, predicts poor outcome in new lesions in 
patients with MS.32 Although not a direct indication, 
these observations are consistent with the concept of 
chronic inflammation and demyelination within and 
at the edge of chronic active lesions as a pathological 
correlate of clinically progressive MS.33
The findings presented here should be considered in 
the context of certain study limitations. The quantita-
tive differences in SEL prevalence between RMS and 
PPMS, with increased numbers and T2 lesion volume 
at baseline in PPMS versus RMS, could be mostly 
reflective of differences in age, gender distribution, 
comparator treatment, and lesion load between these 
patient populations. Furthermore, PPMS and RMS 
studies had different comparator treatment arms and 
2:1 versus 1:1 randomization ratios, respectively. The 
sensitivity of SEL detection may benefit from iso-
tropic 3D acquisitions, is contingent upon the dura-
tion and number of time intervals between MRI scans, 
and limited by the minimal reliability threshold of 
10 voxels for identifying SELs; hence, not all SEL 
candidates might have been identified. In addition, 
determination of thresholds for SEL boundaries in the 
SEL algorithm was decided heuristically; using a differ-
ent set of expansion rates may have generated different 
absolute numbers. Furthermore, the SEL quantification 
algorithm currently does not accommodate potential 
contraction at the lesion center over time,2 which is 
known to be occurring especially in the long term34 
and underscores that the primary pathological process 
in chronically evolving lesions, even those described 
by pathologists as “slowly expanding,” is likely to be 
tissue loss. From an anatomical perspective, it is 
established that chronic accumulation of lesions and 
neurodegeneration in the MS brain does not affect all 
brain regions equally.35 Whether spatial distribution, 
morphological pattern, and severity features of SELs 
might be influenced by venous density, proximity to 
cerebrospinal fluid compartment and/or quality of 
arterial blood supply would warrant dedicated 
investigations.
In summary, our algorithm for the detection of SELs on 
conventional T1- and T2-weighted brain MRI provides 
a novel marker for chronically evolving MS lesion 
pathology, which could be of specific interest to 
advance the understanding of the determinants of clini-
cally apparent progressive disease course. No defini-
tive correlation between SELs and smoldering plaques 
can be drawn without further investigations using other 
imaging techniques and pathological analysis.2
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